BioNTech’s Bold Leap: Navigating Losses and Pioneering Cancer Therapies
BioNTech is transitioning from a focus on COVID-19 vaccines to cancer treatment development. Fourth-quarter 2024 profits dropped, with earnings per share (EPS) at €1.08, yet exceeded market expectations of €0.407…